Literature DB >> 7559918

Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.

W T Klimecki1, C W Taylor, W S Dalton.   

Abstract

We have previously shown that among normal leukocytes, CD56+ and CD8+ cells express relatively high levels of P-glycoprotein (P-gp), a transmembrane efflux pump. While the physiologic significance of P-gp expression in leukocytes is unknown, the relatively high levels of P-gp in CD56+ and CD8+ cells suggest that P-gp may function in cell-mediated cytolysis. To explore this possibility we examined the effect of four inhibitors of P-gp efflux [(R)-verapamil (R-ver), (S)-verapamil (S-ver), cyclosporine A (CsA), and PSC833 (PSC)] on both the inhibition of natural killer cell (NK) function and on P-gp efflux. NK function was assayed by measuring the lysis of 51Cr-labeled K562 target cells in the presence and absence of inhibitors. All four P-gp efflux inhibitors inhibited NK-mediated cytolysis in a dose-dependent manner. The stereoisomers of verapamil were more potent inhibitors of cell-mediated cytolysis than the cyclosporines CsA and PSC. In contrast, CsA and PSC were more potent as inhibitors of P-gp-mediated rhodamine 123 dye efflux than the verapamil isomers. Both CsA and PSC maximally inhibited P-gp efflux at 3 microM, but only minimally inhibited cell-mediated cytolysis. The verapamil compounds demonstrated closer correlation between efflux inhibition of NK-mediated cytolysis. The data support a role for P-gp in NK-mediated cytolysis; however, these studies also suggest that the NK cytolytic process is multifaceted and that inhibition of the P-gp-mediated efflux mechanism only partially abrogates this process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559918     DOI: 10.1007/bf01543107

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

Review 1.  Secretion of peptides and proteins lacking hydrophobic signal sequences: the role of adenosine triphosphate-driven membrane translocators.

Authors:  K Kuchler; J Thorner
Journal:  Endocr Rev       Date:  1992-08       Impact factor: 19.871

Review 2.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

3.  Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.

Authors:  S Yanovich; R E Hall; C Weinert
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

4.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 5.  Resistance of multidrug-resistant lines to natural killer-like cell-mediated cytotoxicity.

Authors:  G Woods; L A Lund; M Naik; V Ling; A Ochi
Journal:  FASEB J       Date:  1988-09       Impact factor: 5.191

6.  Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.

Authors:  B M Foxwell; A Mackie; V Ling; B Ryffel
Journal:  Mol Pharmacol       Date:  1989-10       Impact factor: 4.436

7.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  J Histochem Cytochem       Date:  1989-02       Impact factor: 2.479

8.  Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response.

Authors:  D Kessel; V Botterill; I Wodinsky
Journal:  Cancer Res       Date:  1968-05       Impact factor: 12.701

Review 9.  Mechanism of cytotoxicity by natural killer (NK) cells.

Authors:  R B Herberman; C W Reynolds; J R Ortaldo
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

10.  P-glycoprotein expression and function in circulating blood cells from normal volunteers.

Authors:  W T Klimecki; B W Futscher; T M Grogan; W S Dalton
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

View more
  5 in total

1.  A novel in vivo regulatory role of P-glycoprotein in alloimmunity.

Authors:  Atsushi Izawa; Tobias Schatton; Natasha Y Frank; Takuya Ueno; Kazuhiro Yamaura; Shona S Pendse; Armen Margaryan; Martin Grimm; Martin Gasser; Ana Maria Waaga-Gasser; Mohamed H Sayegh; Markus H Frank
Journal:  Biochem Biophys Res Commun       Date:  2010-03-15       Impact factor: 3.575

2.  Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression.

Authors:  X Y Mu; M P Gosland; M M Bartik; J Schimmelpfennig; N E Kay
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

3.  Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells.

Authors:  Qiuhua Ding; Peiguang Niu; Yanting Zhu; Huajiao Chen; Daohua Shi
Journal:  J Nat Med       Date:  2021-11-09       Impact factor: 2.343

Review 4.  The MDR1 (ABCB1) gene polymorphism and its clinical implications.

Authors:  Ichiro Ieiri; Hiroshi Takane; Kenji Otsubo
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Perplexing Role of P-Glycoprotein in Tumor Microenvironment.

Authors:  Kianna Robinson; Venkataswarup Tiriveedhi
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.